Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Candonilimab + Fruquintinib + Paclitaxel Albumin-Bound in Advanced Gastric or GEJ Adenocarcinoma
NCT07920224Phase 2Recruiting
- Start
- Jul 2025
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cadonilimab and fruquintinib in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma. Primary endpoint: Objective Response Rate up to 1 year. Started Jul 2025; status: recruiting.
02
Drugs
cadonilimabfruquintinib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT07920224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07920224.